Colorectal Cancer - Eight-Market Drug Forecast and Market Analysis

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $10,995	146 Pages	GlobalData	December, 2023	GBDT18536160

Best Price Guarantee
Price	from $10,995
Length	146 Pages
Publisher	GlobalData
Published Date	December, 2023
SKU	GBDT18536160

Colorectal Cancer - Eight-Market Drug Forecast and Market Analysis

Summary

This report covers the 8MM (US, France, Germany, Italy, Spain, UK, Japan, and China) and includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 8MM for marketed and late-stage pipeline therapies, with a launch date assessment by market for Colorectal Cancer (CRC).

These sales forecasts leverage data on pharmaceutical sales and drug availability from GlobalData’s World Markets Healthcare (WMH) and POLI Price Intelligence databases.

CRC, also called osteocolorectal cancer is a rare blood disorder that causes bone marrow (BM) fibrosis. Despite being a rare blood cancer, CRC is a blockbuster market and is expected to grow from sales of $2.39 billion in 2021 to $2.89 billion in 2031 at a compound annual growth rate (CAGR) of 1.9%.

Key Highlights

Report deliverables include a PowerPoint report and Excel-based forecast model
Forecasts includes the 8MM
Forecasts covers from 2021-2031
GlobalData valued the colorectal cancer market in the 8MM at $2.39 billion and expects the market to increase to $2.89 billion by 2031
Incyte, GSK and CTI BioPharma are expected to take market-leading position in 2031
A moderate level of unmet need will remain for most colorectal cancer patient populations during the forecast period
The late-stage pipeline in colorectal cancer is robust and is likely to provide significant clinical benefit to many colorectal cancer patient populations, with fierce competition expected

This report includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 8MM for marketed and late-stage pipeline therapies, with a launch date assessment by market for colorectal cancer (CRC). These sales forecasts leverage data on pharmaceutical sales and drug availability from GlobalData’s World Markets Healthcare (WMH) and POLI Price Intelligence databases.

Despite being a rare blood cancer, CRC is a blockbuster market and is expected to grow from sales of $2.39 billion in 2021 to $2.89 billion in 2031, as shown in Figure 1, at a compound annual growth rate (CAGR) of 1.9%. Peak-year sales are set to be reached in 2027, driven by the approvals of several promising late-stage pipeline agents and the continued clinical dominance of Jakafi/Jakavi (ruxolitinib). In 2028, Jakafi/Jakavi is set to come off-patent in the US, which will greatly decrease its total market sales. However, the loss of total market sales will be somewhat recuperated in 2028 and beyond by the additional growth in market value of other pipeline Janus kinase (JAK) inhibitors and targeted therapies, with sales of these agents being driven by ameliorating critical unmet needs within the CRC treatment paradigm.

Several markets across the 8MM will experience growth driven by common drivers -

Approvals of late-stage pipeline agents, including novel JAK inhibitors and targeted therapies, which will partially meet critical unmet clinical needs
Decreased reliance on generic immunomodulatory agents, androgens, and erythropoietin-stimulating agents
Increased utilization of novel combination regimens with premium-priced agents

Common barriers to market growth experienced across the 8MM primarily include a series of patent expiries:

Patent expiry of Jakafi/Jakavi
Patent expiry of Vonjo (pacritinib)
Patent expiry of Inrebic (fedratinib)

Scope

Overview of colorectal cancer, including epidemiology, symptoms, diagnosis, and disease management.
Annualized colorectal cancer therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2021 to 2031.
Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the colorectal cancer therapeutics market.
Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for colorectal cancer treatment. The most promising candidates in Phase III and Phase IIb development are profiled.
Analysis of the current and future market competition in the global colorectal cancer therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications

Reasons to Buy

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the global colorectal cancer therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global colorectal cancer therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships

Please note:this is delivered as a Zip file.

About GlobalData
1 Colorectal Cancer: Executive Summary: 1.1 The colorectal cancer market will grow to $21.8B by 2031, at a compound annual growth rate of 3.3%; 1.2 Combination therapies and immunotherapies for distinct segments are key R&D strategies in CRC; 1.3 The level of unmet clinical need in colorectal cancer remains high during the forecast period, despite dramatic improvements by historical standards; 1.4 The colorectal cancer pipeline is robust, with plenty of room for new market entrants; 1.5 What do physicians think?
2 Introduction: 2.1 Catalyst; 2.2 Related reports; 2.3 Upcoming reports
3 Disease Overview: 3.1 Etiology and pathophysiology; 3.1.1 Etiology; 3.1.2 Pathophysiology; 3.1.3 Classification and staging systems
4 Epidemiology: 4.1 Disease background; 4.2 Risk factors and comorbidities; 4.3 Global and historical trends; 4.4 Forecast methodology; 4.4.1 Sources; 4.4.2 Forecast assumptions and methods; 4.4.3 Forecast assumptions and methods: diagnosed incident cases of CRC; 4.4.4 Forecast assumptions and methods: diagnosed incident cases of CRC by AJCC stage at diagnosis; 4.4.5 Forecast assumptions and methods: diagnosed incident cases of CRC by recurrence of stages I–III into stage IV disease; 4.4.6 Forecast assumptions and methods: diagnosed incident cases of CRC by molecular markers; 4.4.7 Forecast assumptions and methods: five-year diagnosed prevalent cases of CRC; 4.5 Epidemiological forecast for CRC (2021–31); 4.5.1 Diagnosed incident cases of CRC; 4.5.2 Age-specific diagnosed incident cases of CRC; 4.5.3 Sex-specific diagnosed incident cases of CRC; 4.5.4 Diagnosed incident cases of CRC by AJCC stage at diagnosis; 4.5.5 Diagnosed incident cases of CRC by recurrence of stages I–III intostage IV disease; 4.5.6 Diagnosed incident cases of CRC by molecular markers; 4.5.7 Five-year diagnosed prevalent cases of CRC; 4.6 Discussion; 4.6.1 Epidemiological forecast insight; 4.6.2 COVID-19 impact; 4.6.3 Limitations of the analysis; 4.6.4 Strengths of the analysis
5 Disease Management: 5.1 Diagnosis and Treatment Overview; 5.2 KOL insights on disease management; 5.2.1 US-specific KOL insights on disease management; 5.2.2 5EU-specific KOL insights on disease management; 5.2.3 Japan-specific KOL insights on disease management; 5.2.4 China-specific KOL insights on disease management
6 Current Treatment Options: 6.1 Overview
7 Unmet Needs and Opportunity Assessment: 7.1 Overview; 7.2 Improving treatments for patients with KRAS/NRAS mutations; 7.3 Improving treatment options in precision medicine; 7.4 Overcoming resistance to EGFR- and VEGF-targeted therapies; 7.5 Reduced age for routine disease screening
8 R&D Strategies: 8.1 Overview of R&D strategies; 8.1.1 Targeting MSS patients with immunotherapy; 8.1.2 Combination Therapies; 8.2 Clinical trials design; 8.2.1 Increasing adoption of secondary quality of life endpoints; 8.2.2 Increasing adoption of surrogate endpoints
9 Pipeline Assessment: 9.1 Overview; 9.2 Promising drugs in clinical development
10 Pipeline Valuation Analysis: 10.1 Overview; 10.2 Competitive assessment
11 Current and Future Players: 11.1 Overview; 11.2 Deal-making trends
12 Market Outlook: 12.1 Global Markets; 12.1.1 Forecast; 12.1.2 Drivers and barriers – global issues; 12.2 US; 12.2.1 Forecast; 12.2.2 Key events; 12.2.3 Drivers and barriers; 12.3 5EU; 12.3.1 Forecast; 12.3.2 Key events; 12.3.3 Drivers and barriers; 12.4 Japan; 12.4.1 Forecast; 12.4.2 Key events; 12.4.3 Drivers and barriers; 12.5 China; 12.5.1 Forecast; 12.5.2 Key events; 12.5.3 Drivers and barriers
13 Appendix: 13.1 Bibliography; 13.2 Abbreviations; 13.3 Methodology; 13.3.1 Forecasting methodology; 13.4 Primary research – KOLs interviewed for this report; 13.4.1 KOLs; 13.5 Primary research – prescriber survey; 13.6 About the authors; 13.6.1 Analysts; 13.6.2 Therapy Area Director; 13.6.3 Epidemiologist; 13.6.4 Epidemiology reviewers; 13.6.5 Vice President of Disease Intelligence and Epidemiology
List of Tables: Table 1: Colorectal cancer: key metrics in the 8MM; Table 2: 8MM, TNM staging and classification for CRC; Table 3: 8MM, Diagnosed incident cases of CRC by molecular markers, both sexes, ages ≥18 years, N, 2021; Table 4: CRC screening practices across the 8MM; Table 5: Treatment guidelines for CRC across the 8MM; Table 6: Current landscape of approved CRC agents in the 8MM; Table 7: Comparison of published clinical data for late-stage pipeline agents in CRC; Table 8: Top 10 completed deals by value, 2021-2023; Table 9: CRC market - global drivers and barriers, 2021-2031; Table 10: Key events impacting sales for CRC in the US, 2021-2031; Table 11: CRC market - drivers and barriers in the US, 2021-2031; Table 12: Key events impacting sales for CRC in the 5EU, 2021-2031; Table 13: CRC market - drivers and barriers in the 5EU, 2021-2031; Table 14: Key events impacting sales for CRC in Japan, 2021-2031; Table 15: CRC market - drivers and barriers in Japan, 2021-2031; Table 16: Key events impacting sales for CRC in China, 2021-2031; Table 17: CRC market - drivers and barriers in China, 2021-2031; Table 18: High-prescribing physicians (non-KOLs) surveyed, by country
List of Figures: Figure 1: Global sales forecast by country for CRC in 2021 and 2031; Figure 2: Analysis of the company portfolio gap in CRC during the forecast period; Figure 3: Competitive assessment of the marketed and pipeline drugs benchmarked against Braftovi, targeted therapy agents; Figure 4: Competitive assessment of the marketed and pipeline drugs benchmarked against Keytruda, immunotherapy agents; Figure 5: Risk factors associated with CRC; Figure 6: Tumor sites of the colon and rectum; Figure 7: 8MM, Diagnosed incidence of CRC, men, cases per 100,000 population, ages ≥18 years, 2011–31; Figure 8: 8MM, Diagnosed incidence of CRC, women, cases per 100,000 population, ages ≥18years, 2011–31; Figure 9: 8MM, sources used and not used to forecast the diagnosed incident cases of CRC; Figure 10: 8MM, sources used to forecast the diagnosed incident cases of CRC by stage at diagnosis; Figure 11: 8MM, sources used to forecast the diagnosed incident cases of CRC by recurrence into stage IV disease; Figure 12: 8MM, sources used to forecast the diagnosed incident cases of CRC by molecular markers (KRAS mutation, NRAS mutation, BRAF mutation, BRAF V600E mutation, and PIK3CA/PTEN mutation); Figure 13: 8MM, sources used to forecast the diagnosed incident cases of CRC by molecular markers (MSI-H/dMMR molecular subtype, HER2 amplification, MET amplification, and NTRK gene fusion); Figure 14: 8MM, sources used to forecast the diagnosed incident cases of CRC by molecular markers (DPYD, high TMB, elevated CEA, and UGT1A1 mutation); Figure 15: 8MM, sources used to forecast the diagnosed incident cases of CRC by molecular markers (POLE mutation, TP53 mutation, APC mutation, and PD-L1 expression on tumors); Figure 16: 8MM, Sources used to forecast the five-year diagnosed prevalent cases of CRC; Figure 17: 8MM, Diagnosed incident cases of CRC, N, both sexes, ages ≥18 years, 2021; Figure 18: 8MM, Diagnosed incident cases of CRC by age, N, both sexes, 2021; Figure 19: 8MM, Diagnosed incident cases of CRC by sex, N, all ages, 2021; Figure 20: 8MM, Diagnosed incident cases of CRC by AJCC stage at diagnosis, N, all ages, 2021; Figure 21: 8MM, diagnosed incident cases of CRC by recurrence of stages I–III into stage IV disease, N, both sexes, ages ≥18 years, 2021; Figure 22: 8MM, Five-year diagnosed prevalent cases of CRC, N, both sexes, ages ≥18 years, 2021; Figure 23: Treatment algorithm for localized CRC; Figure 24: Treatment algorithm for advanced/metastatic CRC; Figure 25: Unmet needs and opportunities in CRC; Figure 26: Overview of the ex-China development pipeline in CRC (Phase II–Phase III); Figure 27: Key late-stage trials for targeted therapy CRC candidates that GlobalData expects to be approved in the 8MM during the forecast period; Figure 28: Key late-stage trials for immunotherapy CRC candidates that GlobalData expects to be approved in the 8MM during the forecast period; Figure 29: Competitive assessment of the marketed and pipeline drugs benchmarked against Braftovi, targeted therapy agents; Figure 30: Competitive assessment of the marketed and pipeline drugs benchmarked against Keytruda, immunotherapy agents; Figure 31: Analysis of the company portfolio gap in CRC during the forecast period; Figure 32: Global (8MM) sales forecast by country for CRC in 2021 and 2031; Figure 33: Sales forecast by class for CRC in the US in 2021 and 2031; Figure 34: Sales forecast by class for CRC in the 5EU in 2021 and 2031; Figure 35: Sales forecast by class for CRC in Japan in 2021 and 2031; Figure 36: Sales forecast by class for CRC in China in 2021 and 2033